| Inhibikase Therapeutics, Inc. |
Director |
Common Stock |
765,895 |
$1,286,703 |
$1.68 |
21 Feb 2025 |
Direct |
| Inhibikase Therapeutics, Inc. |
Director |
Stock Option (Right to Buy) |
108,176 |
|
|
30 Jun 2025 |
Direct |
| Longboard Pharmaceuticals, Inc. |
Director |
Stock Option (Right to Buy) |
22,500 |
|
|
23 May 2024 |
Direct |
| ARENA PHARMACEUTICALS INC |
Executive VP and CBO |
Common Stock |
0 |
|
$98.51 |
11 Mar 2022 |
Direct |
| ARENA PHARMACEUTICALS INC |
Executive VP and CBO |
Employee Performance Restricted Stock Unit |
0 |
|
|
11 Mar 2022 |
Direct |
| ARENA PHARMACEUTICALS INC |
Executive VP and CBO |
Employee Stock Option (right to buy) |
0 |
|
|
11 Mar 2022 |
Direct |
| Longboard Pharmaceuticals, Inc. |
Director |
Employee Stock Option (right to buy) |
0 |
|
|
02 Dec 2024 |
Direct |